Literature DB >> 21748603

Surgical outcomes of intrahepatic cholangiocarcinoma.

Masakazu Yamamoto1, Shun-ichi Ariizumi.   

Abstract

Intrahepatic cholangiocarcinoma (ICC) is considered to be a fatal disease because of frequent recurrence despite curative surgery. The macroscopic classification of ICC in the General Rules for the Clinical and Pathological Study of Primary Liver Cancer of the Liver Cancer Study Group of Japan reflects tumor-spreading patterns; therefore, the clinicopathological findings and surgical outcomes can be predicted using this classification. Lymph node and intrahepatic metastases, and a curative resection are important prognostic factors in ICC; however, lymph node dissection is still controversial. In particular, the intraductal growth type and periductal infiltrating type of ICC without hilar invasion have favorable surgical outcomes, whereas the mass-forming type and periductal infiltrating type of ICC with hilar invasion have high hepatic recurrence and local recurrence, respectively. Multimodal treatments are therefore needed to improve the surgical outcomes of ICC.

Entities:  

Mesh:

Year:  2011        PMID: 21748603     DOI: 10.1007/s00595-011-4517-z

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  68 in total

1.  Surgery for periductal infiltrating type intrahepatic cholangiocarcinoma without hilar invasion provides a better outcome than for mass-forming type intrahepatic cholangiocarcinoma without hilar invasion.

Authors:  Kenichiro Imai; Masaklzazu Yamamoto; Shunichi Ariizumi
Journal:  Hepatogastroenterology       Date:  2010 Nov-Dec

2.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Authors:  Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater
Journal:  N Engl J Med       Date:  2010-04-08       Impact factor: 91.245

3.  Intrahepatic cholangiocarcinoma with lymph node metastasis successfully treated by immunotherapy with CD3-activated T cells and dendritic cells after surgery: report of a case.

Authors:  Ryota Higuchi; Masakazu Yamamoto; Takashi Hatori; Koichi Shimizu; Kenichirou Imai; Ken Takasaki
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

Review 4.  Intrahepatic cholangiocarcinoma: macroscopic type and stage classification.

Authors:  Susumu Yamasaki
Journal:  J Hepatobiliary Pancreat Surg       Date:  2003

5.  Intrahepatic cholangiocarcinoma: prognostic factors after surgical resection.

Authors:  Alfredo Guglielmi; Andrea Ruzzenente; Tommaso Campagnaro; Silvia Pachera; Alessandro Valdegamberi; Paola Nicoli; Alessandro Cappellani; Giulio Malfermoni; Calogero Iacono
Journal:  World J Surg       Date:  2009-06       Impact factor: 3.352

6.  Risk factors for intrahepatic cholangiocarcinoma: a case-control study in China.

Authors:  Yan-Ming Zhou; Zheng-Feng Yin; Jia-Mei Yang; Bin Li; Wen-Yu Shao; Feng Xu; Yu-Lan Wang; Dian-Qi Li
Journal:  World J Gastroenterol       Date:  2008-01-28       Impact factor: 5.742

7.  Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution.

Authors:  Michelle L DeOliveira; Steven C Cunningham; John L Cameron; Farin Kamangar; Jordan M Winter; Keith D Lillemoe; Michael A Choti; Charles J Yeo; Richard D Schulick
Journal:  Ann Surg       Date:  2007-05       Impact factor: 12.969

8.  Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans.

Authors:  Hashem B El-Serag; Eric A Engels; Ola Landgren; Elizabeth Chiao; Louise Henderson; Harshinie C Amaratunge; Thomas P Giordano
Journal:  Hepatology       Date:  2009-01       Impact factor: 17.425

9.  Clinicopathological prognostic factors and impact of surgical treatment of mass-forming intrahepatic cholangiocarcinoma.

Authors:  Shohachi Suzuki; Takanori Sakaguchi; Yoshihiro Yokoi; Kazuya Okamoto; Kiyotaka Kurachi; Yasuo Tsuchiya; Takuya Okumura; Hiroyuki Konno; Satoshi Baba; Satoshi Nakamura
Journal:  World J Surg       Date:  2002-03-26       Impact factor: 3.352

10.  Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study.

Authors:  Tania M Welzel; Barry I Graubard; Hashem B El-Serag; Yasser H Shaib; Ann W Hsing; Jessica A Davila; Katherine A McGlynn
Journal:  Clin Gastroenterol Hepatol       Date:  2007-08-06       Impact factor: 11.382

View more
  35 in total

1.  Upregulated expression of Mina53 in cholangiocarcinoma and its clinical significance.

Authors:  Xiao-Ping Tan; Qing Zhang; Wei-Guo Dong; Xia-Wen Lei; Zi-Rong Yang
Journal:  Oncol Lett       Date:  2012-02-28       Impact factor: 2.967

2.  Differentiation of intrahepatic mass-forming cholangiocarcinoma from hepatocellular carcinoma on gadoxetic acid-enhanced liver MR imaging.

Authors:  Rihyeon Kim; Jeong Min Lee; Cheong-Il Shin; Eun Sun Lee; Jeong Hee Yoon; Ijin Joo; Seong Ho Kim; Inpyeong Hwang; Joon Koo Han; Byung Ihn Choi
Journal:  Eur Radiol       Date:  2015-09-15       Impact factor: 5.315

3.  Factors affecting survival after resection of intrahepatic cholangiocarcinoma.

Authors:  Sae Murakami; Tetsuo Ajiki; Taro Okazaki; Kimihiko Ueno; Masahiro Kido; Ippei Matsumoto; Takumi Fukumoto; Yonson Ku
Journal:  Surg Today       Date:  2014-01-23       Impact factor: 2.549

4.  New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing.

Authors:  Jeffrey S Ross; Kai Wang; Laurie Gay; Rami Al-Rohil; Janne V Rand; David M Jones; Hwa J Lee; Christine E Sheehan; Geoff A Otto; Gary Palmer; Roman Yelensky; Doron Lipson; Deborah Morosini; Matthew Hawryluk; Daniel V T Catenacci; Vincent A Miller; Chaitanya Churi; Siraj Ali; Philip J Stephens
Journal:  Oncologist       Date:  2014-02-21

5.  Recognition of other organ involvement might assist in the differential diagnosis of IgG4-associated sclerosing cholangitis without apparent pancreatic involvement: report of two cases.

Authors:  Takeshi Nowatari; Akihiko Kobayashi; Kiyoshi Fukunaga; Tatsuya Oda; Ryoko Sasaki; Nobuhiro Ohkohchi
Journal:  Surg Today       Date:  2012-08-02       Impact factor: 2.549

Review 6.  Intrahepatic cholangiocarcinoma and cholangiolocellular carcinoma in cirrhosis and chronic viral hepatitis.

Authors:  Shun-ichi Ariizumi; Masakazu Yamamoto
Journal:  Surg Today       Date:  2014-09-25       Impact factor: 2.549

7.  Prognostic Impact of Tumor Growth Type on 7th AJCC Staging System for Intrahepatic Cholangiocarcinoma: a Single-Center Experience of 659 Cases.

Authors:  Shin Hwang; Young-Joo Lee; Gi-Won Song; Kwang-Min Park; Ki-Hun Kim; Chul-Soo Ahn; Deok-Bog Moon; Sung-Gyu Lee
Journal:  J Gastrointest Surg       Date:  2015-03-28       Impact factor: 3.452

Review 8.  Transarterial therapies for the treatment of intrahepatic cholangiocarcinoma.

Authors:  Joseph J Zechlinski; William S Rilling
Journal:  Semin Intervent Radiol       Date:  2013-03       Impact factor: 1.513

9.  Curative resection of hilar cholangiocarcinoma in a 25-year-old woman: report of a case.

Authors:  Sae Murakami; Tetsuo Ajiki; Kimihiko Ueno; Hidehiro Sawa; Shinobu Tsuchida; Izuru Otsubo; Yuko Yoshida; Kenta Shinozaki; Taro Okazaki; Ippei Matsumoto; Takumi Fukumoto; Yonson Ku
Journal:  Surg Today       Date:  2013-04-12       Impact factor: 2.549

Review 10.  A review of systemic therapy in biliary tract carcinoma.

Authors:  Holger Jansen; Ulrich-Frank Pape; Nalân Utku
Journal:  J Gastrointest Oncol       Date:  2020-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.